ArticleNature medicine2022

Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.

Irene Ganan-Gomez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.